References
- BuhlRAnti-IgE antibodies for the treatment of asthmaCurr Opin Pulm Med2005111273415591885
- Food and Drug AdministrationFDA approved drug products (Drugs @ FDA), updated August 2011 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfmAccessed August 3, 2011
- American Society for Health-System PharmacistsAHFS Drug Information Essentials: 2004–2005OmalizumabBethesda, MDAmerican Society for Health-System Pharmacists2004
- Medicines and Healthcare Regulatory AgencyOmalizumab: Potential risk of arterial thrombotic events Available from: http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con108718.pdfAccessed August 3, 2011
- World Health OrganizationOmalizumab: Potential risk of arterial thrombotic events2011 Available from: http://www.who.int/medicines/publications/Newsletter_2-2011.pdfAccessed August 3, 2011
- LongAAFishJERahmaouiABaseline characteristics of patients enrolled in EXCELS: a cohort studyAnn Allergy Asthma Immunol2009103321221919788018
- Food and Drug AdministrationPostmarket drug safety information for patients and providersEarly communication about an ongoing safety review of omalizumab (marketed as Xolair)7162009 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm172218.htmAccessed August 3, 2011
- Food and Drug AdministrationAdverse Event Reporting System (AERS): Latest quarterly data files4182011 Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htmAccessed May 12, 2011
- AliAKPharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitorTher Clin Risk Manag2011733734421941439
- Clinical Pharmacology [online database]Tampa, FLGold Standard Inc2011 Available from: http://www.clinicalpharmacology.com. Updated August 2011Accessed March 29, 2012
- BateAEdwardsIRData mining techniques in pharmacovigilanceHartzemaAGTilsonHHChanKAPharmacoepidemiology and Therapeutic Risk Management1st edCincinnati, OHHarvey Whitney Books Co2008
- Food and Drug AdministrationCFR-Code of Federal Regulations Title 21. Updated April 1, 2011 Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32Accessed November 11, 2011
- Food and Drug AdministrationStaff manual guide: Chapter 53; Postmarketing surveillance and epidemiology: human drugsAdverse drug effects. Updated May 12, 2010 Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm129115.htmAccessed November 11, 2011
- Food and Drug AdministrationMedWatch: The FDA Safety Information and Adverse Event Reporting ProgramMedWatch Online Voluntary Reporting Form (3500). Updated October 5, 2011 Available from: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htmAccessed November 13, 2011
- InmanWHWDetection and investigation of drug safety problemsGentMShigamatsuIEpidemiological Issues in Reported Drug-Induced IllnessesOntario, CanadaMcMaster University Library Press1978
- PrandoniPVenous and arterial thrombosis: two aspects of the same disease?Clin Epidemiol200911620865079